Bristol-Myers Squibb (NY:BMY)

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗

September 25, 2024

The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.

Via Benzinga

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability ↗

September 25, 2024

2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval...

Via Benzinga

NYSE:BMY Shows Potential for a Breakout. ↗

September 23, 2024

A technical analysis of BRISTOL-MYERS SQUIBB CO (NYSE:BMY) shows it may be setting up for a breakout.

Via Chartmill

What Analysts Are Saying About Bristol-Myers Squibb Stock ↗

September 16, 2024

Via Benzinga

Current Report: Bristol-Meyers Squibb (BMY) ↗

September 16, 2024

The most recent $0.60 Q dividend was declared September 10th for shareholders of record October 4th and is payable November 1st. There’s time to fetch this payout!

Via Talk Markets

Analysts Think There's Still Time to Get in on Edgewise, Up 332%

September 25, 2024

Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years ↗

September 20, 2024

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental...

Via Benzinga

Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗

September 19, 2024

Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy ↗

September 18, 2024

Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients.

Via Benzinga

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

September 18, 2024

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗

September 16, 2024

Now could be a great time to scoop up three stocks trading way below their previous peaks.

The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.

Merck Scores Two Key Victories With Keytruda In Women's Cancers ↗

September 15, 2024

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

September 15, 2024

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗

September 14, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Via Talk Markets

Topics ETFs

Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024

September 12, 2024

Bristol Myers Squibb Announces Dividend

September 10, 2024

Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗

September 09, 2024

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms

September 09, 2024

These dividend payers could more than double their payouts in the decade ahead.

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗

September 08, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

Via Benzinga

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

September 06, 2024

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗

September 03, 2024

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...

Via Benzinga

Topics Economy

2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High ↗

September 02, 2024

Rebounding growth could make shares of this leading drugmaker a big winner.

No stock is perfect, but quality businesses can stand the test of time in your portfolio.

2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now ↗

September 01, 2024